|
Oct 3
|
AbbVie (ABBV) Suffers a Larger Drop Than the General Market: Key Insights
|
|
Oct 3
|
AbbVie cuts 2024 profit forecast citing R&D expenses
|
|
Oct 3
|
Blue Shield of California Slashes Humira Biosimilar Prices in Landmark Deal
|
|
Oct 3
|
PGIM Jennison Health Sciences Fund Sold AbbVie (ABBV) in Q2. Here’s Why
|
|
Oct 3
|
Investors in AbbVie (NYSE:ABBV) have seen impressive returns of 235% over the past five years
|
|
Oct 3
|
Eli Lilly Leads S&P Health Care Stocks With 1,241% Gain. But The Others Aren't Slackers.
|
|
Oct 2
|
Available Nationwide: JUVÉDERM® VOLUMA® XC for Moderate to Severe Temple Hollowing
|
|
Oct 2
|
5 Best Dividend Growth Stocks to Buy in October
|
|
Oct 2
|
Blue Shield of California sidesteps PBMs with new Humira biosimilar deal
|
|
Oct 2
|
Weight loss drug breakthroughs, gene therapies, and more: 8 clinical trials to watch right now
|
|
Oct 1
|
Should You Buy AbbVie Stock After Recent Parkinson's Study Success?
|
|
Oct 1
|
AbbVie to Host Third-Quarter 2024 Earnings Conference Call
|
|
Sep 30
|
AbbVie Inc. (ABBV) Projects Mid-Single-Digit Sales Growth Over Next 3 Years
|
|
Sep 30
|
AbbVie Seeks Approval for Lung Cancer Candidate Teliso-V
|
|
Sep 30
|
Wall Street Analysts Think AbbVie (ABBV) Is a Good Investment: Is It?
|
|
Sep 30
|
15 Best Dividend Stocks for Lifelong Passive Income
|
|
Sep 29
|
Is AbbVie Inc.'s (NYSE:ABBV) ROE Of 78% Impressive?
|
|
Sep 27
|
15 Unhealthiest Countries in Latin America
|
|
Sep 27
|
ABBV's Newly Added Parkinson's Disease Drug Meets Second Study Goal
|
|
Sep 27
|
AbbVie Submits Biologics License Application to the FDA for Telisotuzumab Vedotin (Teliso-V) in Previously Treated Non-Small Cell Lung Cancer
|